This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Biotech Short-Seller Responds to Critics

NEW YORK ( TheStreet) -- The war against biotech short sellers is heating up once again. Short selling is never going to be a wildly popular investing practice but it is perfectly legal and essential for the proper function of the capital markets. But recently, a public watchdog group in Washington with no expertise in financial markets took the unprecedented step of demanding a criminal investigation of a New York hedge-fund manager simply for engaging in short selling biotech stocks. A vocal minority among Arena Pharmaceutical (ARNA - Get Report) shareholders has taken to shouting "criminal market manipulation" to anyone who vaguely disagrees with their bull thesis; while executives from Ampio Pharmaceuticals (AMPE - Get Report) and Osiris Therapeutics (OSIR - Get Report) use the fear of short sellers and accusations of stock manipulation as a rallying cry for their shareholders.

I asked a biotech short seller for his thoughts on why long investors seem so hostile to short sellers and whether this animosity will compel short sellers to be even more reluctant to voice their opinions publicly.

Here's what he had to say (although as you might expect, he asked to remain anonymous):

"I am a money manager who runs a heavily short-biased book focused on biotech stocks. I ply my craft in relative anonymity, preferring the conversation of other institutional investors to a public forum. Being a short seller has its challenges, some of which result from the behavior of my long only counterparts. They own stocks and resent short sellers making a case for why the stock they own is overvalued. Smart, experienced long investors, however, value learning from someone on the other side of an investment. Sometimes, the long investor will be convinced that I'm right, sell and move on. Other times, his conviction in a long position will be strengthened because he views the short thesis weak or easily debunked. The back-and-forth exchange works both ways.

"What troubles me, however, is the growing propensity for less confident long-only investors to attack the messenger -- short sellers like me -- instead of rigorously debating the short thesis. This bias is perpetuated by many in the media, as in a recent story about Questcor Pharmaceuticals (QCOR) in Investors Business Daily that was topped with the fear-inducing headline, 'Questcor Stock Plummets After Short Seller Attacks.'

"Short sellers 'attack' and must be stopped while investors (a euphemism for long-only buyers) are almost always characterized as being virtuous and good. No thought is given to the possibility that the short thesis might be correct. Enron, anyone? More alarming is how the vilification of short sellers is being pursued. The Justice Department and the Securities and Exchange Commission are urged to launch investigations into short sellers simply because they short stocks --- legally. Public companies are filing lawsuits (or threatening to do so) because an investor expresses a negative opinion. In fact, in some long-only circles, any negative opinion on a stock aired publicly is automatically considered to be manipulation.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMPE $4.20 0.48%
ARNA $1.58 -2.47%
QCOR $93.60 1.65%
OSIR $5.01 -6.00%
AAPL $94.19 -1.04%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs